Investigational Drug Cediranib Shows Promise In Patients With Recurrent Glioblastoma

Armen Hareyan's picture

Recurrent Glioblastoma


Data for the investigational agent cediranib were presented from a study in patients with recurrent glioblastoma, an invasive form of brain tumor with a high unmet medical need.

Cediranib Phase II monotherapy study in recurrent glioblastoma

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.